TTR and amyloidosis: Effective systemic treatments, including liver transplantation and disease-modifying drugs (tafamidis and patisiran), slow disease progression and increase the survival rate among patients with hATTR amyloidosis; however, the frequencies of ocular symptoms are increased because TTR is produced in the liver and eyes [16–19].